Home›Trial›NCT04540497
🔬NCT04540497Phase 3ACTIVE NOT RECRUITING

A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

Study Summary

This study aims to evaluate the efficacy and safety of inebilizumab for the prevention of flare of Immunoglobulin G4-related disease (IgG4-RD).

Conditions
IgG4 Related Disease
Interventions / Drugs
InebilizumabPlacebo
View on ClinicalTrials.gov ↗
Sponsor
AMGN
Amgen Inc
Biologics
F33/100
Study Details
Enrollment135 participants
Primary Completion—
Lead SponsorAmgen
Data Retrieved2026-04-13 18:29:34.158126+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.